Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
AbbVie Inc. manufactures AndroGel 1% and AndroGel 1.62% — prescription testosterone gels applied to the skin daily. At its commercial peak around 2012–2014, AndroGel generated over $1 billion annually in U.S. sales, fueled by a massive "Low T" direct-to-consumer advertising campaign that encouraged men to self-diagnose testosterone deficiency based on symptoms of normal aging.
Clinical research — including a 2013 JAMA study of 55,000 VA patients and the FDA's own 2014 safety review — found significant cardiovascular risk in AndroGel users. The FDA issued a black box warning in 2015. MDL 2545 in the Northern District of Illinois consolidated over 10,000 cases against AbbVie alone. After multiple bellwether trials with mixed results, AbbVie reached a confidential global settlement estimated at $250M–$500M for its MDL inventory.
The full investigation